Use of hormonal contraception in adolescents: Skeletal health issues

Current Opinion in Obstetrics and Gynecology

Volumn 21, Issue 5, 2009, Pages 396-401

  Tolaymat, Lama L ^a   Kaunitz, Andrew M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescents; Bone; Bone mineral density; Contraception

Indexed keywords

ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

BONE DENSITY; ENDOCRINE DISEASE; FRACTURE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HORMONAL CONTRACEPTION; HORMONE SYNTHESIS; HUMAN; HYPOESTROGENISM; INTRAUTERINE CONTRACEPTIVE DEVICE; LACTATION; MEDICAL LITERATURE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKELETON; UNITED STATES;

ADOLESCENT; ADOLESCENT DEVELOPMENT; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; YOUNG ADULT;

EID: 70349126911     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32832c9cc6     Document Type: Review

References (51)

1. Teegarden D, Proulx WR, Martin BR, et al. Peak bone mass in young women.J Bone Miner Res 1996; 10:711-715.
2. Harel Z, Gold M, Cromer B, et al. Bone mineral density in postmenarchaladolescent girls in the United States: associated biopsychosocial variablesand bone turnover markers. J Adolesc Health 2007; 40:44-53.
3. Pitts SAB, Emans SJ. Controversies in contraception. Curr Opin Pediatr2008; 20:383-389.
4. Caird LE, Reid-Thomas V, Hannan WJ, et al. Oral progestogen-only contraceptionmay protect against loss of bone mass in breast-feeding women. Clin Endocrinol (Oxf) 1994; 41:739-745.
5. Surrey ES, Hornstein MD, for the Add-Back Study Group. Prolonged GnRHagonist and add-back therapy for symptomatic endometriosis: long-termfollow-up. Obstet Gynecol 2002; 99:709-719.
6. Weiner E, Victor A, Johansson ED. Plasma levels of d-norgestrel after oraladministration. Contraception 1976; 14:563-570.
7. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterinedevice. Ann Med 1990; 22:85-90.
8. Beerthuizen R, Van Beek A, Massai R, et al. Bone mineral density duringlong-term use of the progestagen contraceptive implant Implanon comparedto a nonhormonal method of contraception. Hum Reprod 2000; 15:118-122.
9. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): ahighly effective contraceptive option with proven long-term safety. Contraception2003; 68:75-87.
10. Tolaymat LL, Kaunitz AM. Long acting contraceptives in adolescents. Curr Opin Obstet Gynecol 2007; 19:453-460.
11. Kaunitz AM. Long acting hormonal contraceptives indispensable in preventingteen pregnancy. J Adolesc Health 2007; 40:1-3.
12. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetatecontraception. J Reprod Med 1996; 41:381-390.
13. Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability ofsequential estradiol and progesterone concentrations in women using depotmedroxyprogesterone acetate for contraception. Fertil Steril 2001; 75:871-877.
14. Gbolade BA. Depo-Provera and bone density. J Fam Plann Reprod Health Care 2002; 28:7-11.
15. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture inwhite women. Study of Osteoporotic Fractures Research Group. N Engl JMed 1995; 332:767-773.
16. McClung MR. The relationship between bone mineral density and fracturerisk. Curr Osteoporos Rep 2005; 3:57-63.
17. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous toyour health. Obstet Gynecol 2005; 105:1114-1118.
18. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004; 20:341-349.
19. Curtis KM, Martins SL. Progesten-only contraception and bone mineraldensity: a systematic review. Contraception 2006; 73:470-487.
20. Kaunitz AM. Beyond the pill: new data and options in hormonal and intrauterinecontraception. Am J Obstet Gynecol 2005; 192:998-1004.
21. Scholes D, Lacroix AZ, Ichikawa LE, et al. Change in bone mineral densityamong adolescent women using and discontinuing depot medroxyprogesteroneacetate contraception. Arch Pediatr Adolesc Med 2005; 159:139-144.
22. Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescentfemales using injectable or oral contraceptives: a 24 months prospectivestudy. Fertil Steril 2008; 90:2060-2067.
23. Rosenberg L, Zhang Y, Constant D, et al. Bone status after cessation of use ofinjectable progestin contraceptives. Contraception 2007; 76:425-431.
24. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesteroneacetate and 20-microgram oral contraceptives on bone mineraldensity. Obstet Gynecol 2008; 112:788-799.
25. Vestergaard P, Rejnmark L, Mosekilde L. The effect of depot medroxyprogesteroneacetate and intrauterine device use on fracture risk in Danish women. Contraception 2008; 78:459-464.
26. WHO. WHO statement on hormonal contraception and bone health. Wkly Epidemiol Rec 2005; 80:302-304.
27. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesteroneacetate and bone mineral density in adolescents-the black box warning: aposition paper of the society for adolescent medicine. J Adolesc Health 2006;39:296-301.
28. Black A. Canadian contraception consensus: update on depot medroxyprogesteroneacetate (DMPA). J Obstet Gynaecol Can 2006; 28:305-313.
29. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: depot medroxyprogesteroneacetate and bone effects. Obstet Gynecol 2008; 112:727-730.
30. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesteroneacetate injectable contraception use. Contraception 2008;77:67-76.This review article examines the evidence regarding BMD trends after discontinuationof DMPA use. The authors found that bone loss occurring during DMPAuse is reversible and is not likely to be an important risk factor for low BMD andfractures in older women.
31. Paschall S, Kaunitz AM. Depo-Provera and skeletal health: a survey of Floridaobstetrics and gynecologists physicians. Contraception 2008; 78:370-376.
32. Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary ovarian axissuppression with three oral contraceptive regimens. Contraception 2008;77:162-170.
33. Gambacciani M, Cappagli B, Lazzarini V, et al. Longitudinal evaluation ofperimenopausal bone loss: effects of different low dose oral contraceptivepreparations on bone mineral density. Maturitas 2006; 54:176-180.
34. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception andbone health: a systematic review. Contraception 2006; 73:445-469.
35. Pikkarainen E, Lehtonen-Veromaa M, Mö ttö nen T, et al. Estrogen-progestincontraceptive use during adolescence prevents bone mass acquisition: a4-year follow-up study. Contraception 2008; 78:226-231.
36. Polatti F, Perotti F, Filippa N, et al. Bone mass and long-term monophasic oralcontraceptive treatment in young women. Contraception 1995; 51:221-225.
37. Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bonedensity in adolescent girls receiving depot medroxyprogesterone acetate(Depot Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr1996; 129:671-676.
38. Cromer BA, Binkovitz L, Ziegler J, et al. Reference values for bone mineraldensity in 12-18 year old girls categorized by weight, race and age. Pediatr Radiol 2004; 34:787-792.
39. Barad D, Kooperberg C, Wactawski-Wende J, et al. Prior oral contraceptionand postmenopausal fracture: a women's health initiative observational cohortstudy. Fertil Steril 2005; 84:374-383.
40. Michaelsson K, Baron JA, Farahmand B, et al. Oral contraceptive use and riskof hip fracture: a case-control study. Lancet 1999; 353:1481-1484.
41. Kaunitz AM. Clinical practice, hormonal contraception in women of older reproductive age. N Engl J Med 2008; 358:1262-1270.
42. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in very young womenusing combined oral contraceptives. Contraception 2008; 78:358-364.
43. Kalkwarf HJ. Lactation and maternal bone health. Adv Exp Med Biol 2004;554:101-114.
44. Polatti F, Capuzzo E, Viazzo F, et al. Bone mineral changes during and afterlactation. Obstet Gynecol 1999; 94:52-56.
45. Hayslip CC, Klein TA, Wray HL, Duncan WE. The effects of lactation on bonemineral content in healthy postpartum women. Obstet Gynecol 1989;73:588-592.
46. Kalkwarf HJ, Specker BL. Bone mineral loss during lactation and recoveryafter weaning. Obstet Gynecol 1995; 86:26-32.
47. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversiblebone loss in human. Osteoporos Int 2001; 12:828-834.
48. Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers andsubsequent bone mineral density. Arch Pediatr Adolesc Med 2004;158:650-656.
49. Honda A, Kurabayashi T, Yahata T, et al. Lumbar bone mineral densitychanges during pregnancy and lactation. Int J Gynaecol Obstet 1998; 63:253-325.
50. Sowers MF, School T, Harris L, et al. Bone loss in adolescents and adultpregnant women. Obstet Gynecol 2000; 96:189-193.
51. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Influence of parity andlactation on hip fracture risk. Am J Epidemiol 2001; 153:1166-1172.